Comparative Pharmacology
Head-to-head clinical analysis: OMNIPEN N versus PROBAMPACIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OMNIPEN N versus PROBAMPACIN.
OMNIPEN-N vs PROBAMPACIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Omnipen-N (ampicillin sodium) is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby interfering with transpeptidation and resulting in cell lysis.
PROBAMPACIN is a synthetic aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, causing misreading of mRNA and preventing translocation of peptidyl-tRNA from the A-site to the P-site.
250-500 mg orally every 6 hours for adults; for severe infections, up to 1 g every 6 hours.
100 mg IV every 12 hours over 30 minutes.
None Documented
None Documented
30-60 minutes (normal renal function); prolonged to 7-10 hours in severe renal impairment (CrCl <10 mL/min).
4.5 hours (prolonged to 12-18 hours in severe renal impairment)
Primarily renal (80-90% unchanged via tubular secretion); minor biliary/fecal (<10%).
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic